Aohua has raised $75.0M in total across 2 funding rounds.
Aohua's investors include Qiming Venture Partners.
Aohua is a leading Chinese technology company specializing in the development, manufacturing, and marketing of flexible endoscopy systems and related peripheral devices. Its products serve hospitals and healthcare providers worldwide, aiming to improve clinical outcomes by enabling more accurate, less invasive diagnostic and treatment procedures. Aohua’s endoscopy solutions address critical challenges in medical imaging, reducing patient suffering and hospital stays while enhancing diagnostic precision. The company has demonstrated strong growth momentum, expanding its global footprint to over 80 countries and continuously innovating with advanced imaging technologies such as 4K ultra-high-definition video endoscopy[1][3].
Founded in 1994 in Shanghai, Aohua began as one of China’s earliest high-tech enterprises focused on endoscopy. The founders, leveraging their expertise in medical imaging and engineering, sought to make cutting-edge endoscopic technologies more accessible to healthcare facilities. Early milestones include launching China’s first video endoscopy system in 2005 and subsequent innovations like the high-definition AQ-100 system in 2011 and the 4K AQ-300 system in 2022. These pivotal developments helped establish Aohua’s reputation and market presence, supported by a strong R&D team of over 150 personnel and multiple production bases[1][3].
Aohua rides the global trend toward minimally invasive medical procedures and digital healthcare transformation. The timing is favorable due to increasing demand for advanced diagnostic tools that improve patient outcomes and reduce healthcare costs. Market forces such as aging populations, rising chronic diseases, and healthcare infrastructure modernization in emerging markets support Aohua’s growth. By advancing endoscopy technology, Aohua influences the broader medical technology ecosystem, enabling more precise diagnostics and expanding applications across multiple clinical specialties beyond gastroenterology, including respiratory and ENT[3].
Looking ahead, Aohua is poised to deepen its innovation in flexible endoscopy, potentially integrating AI and enhanced imaging analytics to further improve diagnostic accuracy and workflow efficiency. Trends like telemedicine and personalized medicine may also shape its product development. As it expands its global presence and technological capabilities, Aohua’s influence in the medical device sector is likely to grow, reinforcing its mission to make endoscopy diagnosis and treatment more accessible and convenient worldwide[3][5].
Aohua has raised $75.0M across 2 funding rounds. Most recently, it raised $44.0M Series D in September 2018.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2018 | $44.0M Series D | Qiming Venture Partners | |
| Dec 1, 2015 | $31.0M Series C | Qiming Venture Partners |
